Search results for "Glycosaminoglycan"

showing 10 items of 73 documents

Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled s…

2008

Since very little is understood about the exact aetiology of tinnitus, this has made treatment of the condition difficult. Even though approximately 10-15% of the general population suffer from tinnitus, only 2% consider it serious enough to warrant any treatment. The main problem arising from tinnitus is the disturbance it causes not only in day to day life but also in sleep, leading to fatigue and general discomfort. The present study focused on the effect of Melatonin in conjunction with Sulodexide as a treatment method for tinnitus. Overall, 102 patients suffering from tinnitus were evaluated in a prospective randomised controlled study conducted in a tertiary care ENT department. After…

AdultMaleMelatonin sulodexideAcufenometryAdministration OralTinnitus handicap inventoryOtologyHearing lossMiddle AgedTinnitusotorhinolaryngologic diseasesHumansFemaleProspective StudiesMedical treatmentGlycosaminoglycansMelatoninActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
researchProduct

The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects

2013

Abstract Objectives The objectives of this study are to quantify endurance and respiratory function and better characterize spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects. Methods MorCAP was a multicenter, multinational, cross sectional study amended to be longitudinal in 2011. Each study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels. Results Data from the first visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean ± SD height z-scores were − 5.6 ± 3.1 as determined by the CDC growth charts. Mean ± SD from the 6-minute-walk-test was 212.6 ± 152.2 m, revealing limitation…

AdultMaleVital capacitymedicine.medical_specialtyAdolescentCross-sectional studyEndocrinology Diabetes and MetabolismMucopolysaccharidosisMotor ActivityBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyElosulfase alfaQuality of lifeSurveys and QuestionnairesInternal medicineActivities of Daily LivingGeneticsmedicineHumansMedical historyRespiratory functionChildExerciseMolecular BiologyGlycosaminoglycans030304 developmental biology0303 health sciencesbusiness.industryInfant NewbornInfantMucopolysaccharidosis IVmedicine.diseaseUnited StatesRespiratory Function TestsCross-Sectional StudieschemistryKeratan SulfateChild PreschoolPhysical EnduranceQuality of LifeMucopolysaccharidosis IVPhysical therapyFemalebusiness030217 neurology & neurosurgeryMolecular Genetics and Metabolism
researchProduct

Insulin-dependent diabetes mellitus and glycosaminoglycans.

1995

The influence of diabetic nephropathy on urinary glycosaminoglycan distribution was assessed in 96 patients with insulin-dependent diabetes mellitus (IDDM, 49 female, age: 16 - 64 yrs, median 35; duration of IDDM: 0 - 43 yrs, median 13 yrs) in comparison to 103 healthy controls (57 female, 17 - 82 yrs, median 40 yrs). Glycosaminoglycan concentration of 24 h urine samples was determined by means of precipitation with cethylpyridinium chloride and potassium acetate in ethanol followed by a colorimetric test with carbazole. A marked difference (p = 0.0008) in urinary glycosaminoglycan excretion between patients (19.0, 12.4, 35.6 mg/24 h, median, 25th, 75th percentile) and controls (15.8, 10.4,…

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismUrinary systemClinical BiochemistryBiochemistryNephropathyDiabetic nephropathyExcretionGlycosaminoglycanEndocrinologyDiabetes mellitusInternal medicinemedicineHumansDiabetic NephropathiesAgedGlycosaminoglycansAged 80 and overDiabetic Retinopathybusiness.industryBiochemistry (medical)General MedicineMiddle Agedmedicine.diseaseUrinary glycosaminoglycan excretionEndocrinologyDiabetes Mellitus Type 1FemalebusinessRetinopathyHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
researchProduct

Glycosaminoglycan Antibodies in Endocrine Ophthalmopathy

1993

An increased accumulation of glycosaminoglycans (GAG) in the orbita has been reported in endocrine ophthalmopathy (EO). In this study we investigated whether antibodies directed against GAG are present in the sera of 52 EO patients and 47 healthy controls. Three out of 52 patients exhibited low titers of antinuclear antibodies and all patients were negative for antibodies against extractable nuclear antigens. Isotype IgG antibodies were detected by means of an ELISA using hyaluronic acid and dermatan sulfate as antigens. Values were expressed as optical density at 405 nm. In comparison to the control group (0.445, 0.364, 0.588; median, 25th, 75th percentile) significantly (p < 0.001) higher…

AdultMalemedicine.medical_specialtyAdolescentEye DiseasesAnti-nuclear antibodyExtractable nuclear antigensEndocrinology Diabetes and MetabolismClinical BiochemistryDermatan SulfateBiochemistryDermatan sulfatechemistry.chemical_compoundEndocrinologyAntigenInternal medicineHyaluronic acidmedicineHumansHyaluronic AcidAgedAutoantibodiesGlycosaminoglycansAged 80 and overbiologybusiness.industryBiochemistry (medical)ThyroidAutoantibodyGeneral MedicineMiddle AgedThyroid Diseasesmedicine.anatomical_structureEndocrinologychemistryImmunologybiology.proteinFemaleAntibodybusinessHormone and Metabolic Research
researchProduct

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

2011

The mucopolysaccharidoses (MPSs) are inherited lysosomal storage disorders caused by the absence of functional enzymes that contribute to the degradation of glycosaminoglycans (GAGs). The progressive systemic deposition of GAGs results in multi-organ system dysfunction that varies with the particular GAG deposited and the specific enzyme mutation(s) present. Cardiac involvement has been reported in all MPS syndromes and is a common and early feature, particularly for those with MPS I, II, and VI. Cardiac valve thickening, dysfunction (more severe for left-sided than for right-sided valves), and hypertrophy are commonly present; conduction abnormalities, coronary artery and other vascular in…

AdultMalemedicine.medical_specialtyAdolescentMucopolysaccharidosisClinical SciencesHeart Valve DiseasesReviewComorbidityCoronary Artery DiseaseDiseaseMuscle hypertrophyCoronary artery diseaseElectrocardiographyVentricular hypertrophyTachycardiaInternal medicineGeneticsmedicineHumansGenetics(clinical)Age of OnsetSinusChildPreschoolGenetics (clinical)GlycosaminoglycansGenetics & Hereditymedicine.diagnostic_testbusiness.industryMitral Valve InsufficiencyHypertrophyAortic Valve StenosisEnzyme replacement therapyMucopolysaccharidosesMiddle Agedmedicine.diseaseLeft VentricularCausalityTachycardia SinusEchocardiographyChild PreschoolAortic valve stenosisCardiologyHypertrophy Left VentricularFemalebusinessElectrocardiographyJournal of Inherited Metabolic Disease
researchProduct

Urinary glycosaminoglycans in Graves' ophthalmopathy.

1990

An increased accumulation of glycosaminoglycans (GAG) in retrobulbar tissues has been reported in patients with thyroid eye disease. We examined the quantitative urinary GAG excretion in 101 patients with Graves' ophthalmopathy of different classes, 36 patients with Graves' hyperthyroidism without ophthalmopathy, 14 patients with toxic nodular goitre and 103 control subjects. Glycosaminoglycans were isolated from 24-h urine collections by precipitation with cetylpyridinium chloride and ethanol followed by photometrical quantification of hexuronic acids after reaction with carbazole. In comparison with the control group (15.8, 10.4, 21.6 mg/24 h; median, 25th, 75th percentile) a significant …

AdultMalemedicine.medical_specialtyGoiterAdolescentEndocrinology Diabetes and MetabolismGraves' diseaseUrinary systemUrineGraves' ophthalmopathyExcretionEndocrinologyInternal medicineImmunopathologymedicineHumansAgedGlycosaminoglycansAged 80 and overbusiness.industryThyroidMiddle Agedmedicine.diseaseCombined Modality TherapyGraves DiseaseEndocrinologymedicine.anatomical_structurePrednisoneFemalebusinessGoiter NodularClinical endocrinology
researchProduct

Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series.

2012

To assess clinical features and general health status of adult patients with mucopolysaccharidosis (MPS) VI. This report includes the clinical history of patients older than 18 years with slowly progressing MPS VI and the retrospective analysis of the outcomes of available data collected between September 2003 and October 2008 at the Center of Pediatric and Adolescent Medicine, University Medical Center, Johannes Gutenberg-University of Mainz, Germany. Variables included were urinary glycosaminoglycan (uGAG) level, mutation analysis, body height, forced vital capacity (FVC), 6-minute walk test, echocardiographic findings, the need for craniocervical decompression surgery, orthopaedic findin…

AdultMalemedicine.medical_specialtyN-Acetylgalactosamine-4-SulfataseMucopolysaccharidosismedicine.medical_treatmentCarpal tunnel surgeryFEV1/FVC ratioAdolescent medicineYoung AdultValve replacementGermanyGeneticsmedicineHumansAge of OnsetCarpal tunnel syndromeGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis VIbusiness.industryMucopolysaccharidosis VIEnzyme replacement therapymedicine.diseaseSurgeryPhenotypeDisease ProgressionFemalebusinessFollow-Up StudiesJournal of inherited metabolic disease
researchProduct

Sulodexide versus calcium heparin in the medium-term treatment of deep vein thrombosis of the lower limbs.

1997

Thirty adult patients with distal, monolateral deep vein thrombosis of the lower limbs were randomly treated for sixty days either with subcutaneous Ca-Heparin or with Sulodexide, administered IM for ten days and orally for fifty days. The thrombus accretion above the knee, the venous pressures of the affected leg, the clinical sympto matology, and some laboratory coagulative tests were monitored throughout the admin istration period. Local tolerability of the two treatments was also evaluated.The two applied treatments evidenced a net antithrombotic activity, preventing thrombus accretion above the knee, improving with the same efficacy the venous pressures in the affected legs, and simila…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.drug_classDeep vein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsHumansMedicine030212 general & internal medicineThrombusAgedGlycosaminoglycansmedicine.diagnostic_testHeparinbusiness.industryAnticoagulantHeparinMiddle AgedThrombophlebitismedicine.diseaseThrombosisSulodexideSurgerymedicine.anatomical_structureTolerabilityAnesthesiaSettore BIO/14 - FarmacologiaFemaleAdult Aged Female Fibrinolytic Agents/administration & dosage Fibrinolytic Agents/therapeutic use* Glycosaminoglycans/administration & dosage Glycosaminoglycans/therapeutic use* Heparin/therapeutic use* Humans Male Middle Aged Thrombophlebitis/drug therapy*Cardiology and Cardiovascular Medicinebusinessmedicine.drugPartial thromboplastin time
researchProduct

Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias

2007

Very low density lipoprotein (VLDL) 1 and 2 were fractionated by heparin affinity chromatography into a bound and an unbound fraction and the different subfractions were quantified in 17 normolipidaemic (NL), 13 hypercholesterolaemic (HC), 10 hypertriglyceridaemic (HTG) and 11 combined hyperlipidaemic subjects (CHL). Unbound VLDL1 and VLDL2 were, respectively, 1.9- and 2.2-fold richer in triglycerides than bound VLDL1 and VLDL2. In HTG and CHL the concentration of all the VLDL subfractions was increased and plasma triglyceride level was correlated to unbound VLDL1 and to bound VLDL1 (respectively, r=0.86 (p<0.001) and r=0.77 (p<0.01) in HTG and r=0.73 (p<0.001) and r=0.62 (p<0.05) in CHL). …

AdultMalemedicine.medical_specialtyVery low-density lipoproteinHypercholesterolemiaHyperlipidemia Familial CombinedLipoproteins VLDLChromatography AffinityGlycosaminoglycanchemistry.chemical_compoundAffinity chromatographyInternal medicinemedicineHumansApolipoproteins BDyslipidemiasHypertriglyceridemiaTriglycerideHeparinCholesterolHypertriglyceridemiaAnticoagulantsHeparinMiddle Agedmedicine.diseaseEndocrinologychemistryFemaleCardiology and Cardiovascular MedicineUltracentrifugationProtein BindingLipoproteinmedicine.drugAtherosclerosis
researchProduct

Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.

2011

Purpose: To use the Hunter Outcome Survey, an international database, to assess the safety and effectiveness of enzyme replacement therapy with idursulfase in patients with Hunter syndrome who started treatment before 6 years of age. Methods: The study population included all patients enrolled in the Hunter Outcome Survey who started idursulfase infusions (0.5 mg/kg every other week) before 6 years of age and who had at least one follow-up examination recorded. Results: The study population included 124 patients, younger than 6 years, who had a mean age at start of idursulfase of 3.6 ± 1.6 years (mean ± SD). The mean duration of treatment was 22.9 ± 14.6 months. A total of 69 infusion-relat…

AdultPediatricsmedicine.medical_specialtyAdolescentDatabases FactualIdursulfaseUrineIduronate Sulfatasechemistry.chemical_compoundYoung AdultInternational databaseMedicineHumansEnzyme Replacement TherapyYoung adultChildInfusions IntravenousGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis IICreatinineClinical Trials as Topicbusiness.industryData CollectionInfantHunter syndromeEnzyme replacement therapymedicine.diseaseTreatment OutcomechemistryChild PreschoolPopulation studybusinessmedicine.drugGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct